Full Breakdown
Growing Interest in Alzheimer’s Blood Tests: A Study's Findings
4/17/2026, 11:08:56 PM
Overview of the Study
A recent study led by Andrea Russell, a psychologist at Northwestern University, reveals that a significant majority of older adults are open to taking a blood test to assess their risk of Alzheimer’s disease. Published in *Alzheimer’s & Dementia: The Journal of the Alzheimer’s Association*, the study surveyed nearly 600 primary care patients, with 85% expressing willingness to undergo the test, despite concerns about potential emotional distress from positive results.
The Blood Test and Its Implications
The blood tests in question measure levels of amyloid and tau proteins, which are associated with Alzheimer’s pathology. Although the U.S. Food and Drug Administration (FDA) cleared two blood tests for individuals aged 55 and older with symptoms in 2025, awareness remains low, with 84% of respondents unaware of their existence. Russell noted that many patients experience anxiety regarding cognitive decline, leading them to prefer proactive measures, even if the tests could induce distress.
Key Findings from the Survey
The survey highlighted several important insights:
- Willingness to Act: Approximately 87% of participants indicated they would take steps to improve their brain health if they received a positive test result.
- Barriers to Testing: The primary concerns included the cost (49%), reliability of the tests (35%), and fear of being treated differently after a positive result (24%).
- Desire for Information: Participants expressed a strong interest in receiving information about their cognitive health, with 94.5% considering it important to offer these tests to those with memory issues.
Advancements in Blood Testing for Alzheimer’s
In parallel, research from Mass General Brigham has focused on the potential of the phosphorylated tau 217 (pTau217) blood test. This test aims to detect Alzheimer’s pathology earlier than traditional methods, such as PET scans. The study followed 317 cognitively healthy adults over an average of eight years, revealing that elevated pTau217 levels could predict cognitive decline and amyloid buildup before PET scans showed abnormalities.
Criticism and Concerns
Despite the promising findings, experts caution against the routine use of these tests in cognitively healthy individuals. Concerns include the potential for false positives and the emotional impact of receiving a positive result without clear guidance on next steps. Dr. Andrea Bozoki, a neurologist not involved in the study, noted that many individuals with positive biomarkers do not develop cognitive symptoms, complicating the interpretation of results.
Future Directions
As research continues to evolve, the hope is that blood tests like pTau217 will become integral to routine health assessments for older adults. The findings from Russell's survey and the Mass General Brigham study suggest a growing acceptance and demand for these tests, which could lead to earlier interventions and improved management of Alzheimer’s disease.
Verbatim Quotes
- “Some are afraid to leave the house because they worry they’ll forget something or get lost. Others don’t want to know what’s happening because there is so much doom and gloom around Alzheimer’s. For many people, it feels like the new cancer diagnosis.” — Andrea Russell, Psychologist, Northwestern University
- “What’s healthy for the brain is healthy for the body,” — Andrea Russell, Psychologist, Northwestern University
- “By anticipating who’s going to turn amyloid-positive in the future, we are trying to push back the clock to enable earlier Alzheimer’s disease prediction.” — Jasmeer Chhatwal, MD, PhD, Mass General Brigham
The study underscores the importance of understanding public perception and readiness for Alzheimer’s blood tests, which could significantly impact early detection and intervention strategies in the future.
